Australia markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.60-0.22 (-1.31%)
At close: 04:00PM EDT
16.75 +0.15 (+0.90%)
After hours: 06:38PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.31B
Enterprise value 1.33B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.90
Price/book (mrq)2.24
Enterprise value/revenue 4.02
Enterprise value/EBITDA -7.38

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3-33.92%
S&P500 52-week change 321.23%
52-week high 333.31
52-week low 315.45
50-day moving average 319.19
200-day moving average 321.12

Share statistics

Avg vol (3-month) 31.19M
Avg vol (10-day) 31.04M
Shares outstanding 5139.16M
Implied shares outstanding 6143.17M
Float 8120.16M
% held by insiders 113.79%
% held by institutions 179.51%
Shares short (28 Mar 2024) 49.41M
Short ratio (28 Mar 2024) 47.82
Short % of float (28 Mar 2024) 48.02%
Short % of shares outstanding (28 Mar 2024) 46.77%
Shares short (prior month 29 Feb 2024) 48.87M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -43.94%
Operating margin (ttm)-59.51%

Management effectiveness

Return on assets (ttm)-9.40%
Return on equity (ttm)-14.01%

Income statement

Revenue (ttm)330.53M
Revenue per share (ttm)2.41
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -187.87M
Net income avi to common (ttm)-145.22M
Diluted EPS (ttm)-1.06
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.03B
Total cash per share (mrq)7.43
Total debt (mrq)52.24M
Total debt/equity (mrq)5.07%
Current ratio (mrq)13.65
Book value per share (mrq)7.45

Cash flow statement

Operating cash flow (ttm)-357.99M
Levered free cash flow (ttm)-298.35M